1-6 of 6
Nelma Clementino, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Nelson Spector, MD, PhD, Brian Leber, MD, Ricardo Pasquini, MD, PhD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Gabriel Etienne, MD, PhD, Agnès Guerci-Bresler, MD, Susan Branford, PhD, Das Purkayastha, LaTonya Collins, BSN, Tomasz Szczudlo, Francisco Cervantes, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 694.
https://doi.org/10.1182/blood.V120.21.694.694
Published: 2012
Journal Articles

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

Katia B. Pagnano, MD, Israel Bendit, MD, Carla Boquimpani, Carmino Antonio De Souza, MD, PhD, Eliana C M Miranda, Rosana A Silveira, Vaneuza A M Funke, MD, Ricardo Pasquini, MD, Vania Hungria, MD, Nelma Clementino, MD, Monika Conchon, Elena B Moiraghi, MD, Jose L. Lopez, MD, Carolina Pavlovsky, MD, Eduardo Cervera, Belinda Pinto Simoes, MD, PhD, Luis A Meillon, MD, Nelson Spector, MD, PhD, Nelson Hamerschlak, MD, Miguel Pavlovsky, Alicia Magarinos, MD, Vagner O Duarte, Ernesto M Fanilla, Jorge E. Cortes, Raquel Bengió, MD
Journal: Blood
Blood (2011) 118 (21): 1701.
https://doi.org/10.1182/blood.V118.21.1701.1701
Published: 2011
Journal Articles

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Brian Leber, MD, Nelson Spector, MD, PhD, Francisco Cervantes, MD, PhD, Ricardo Pasquini, MD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Suzanne Kamel-Reid, PhD, Israel Bendit, MD, John Reynolds, PhD, Lisa Williams, Tomasz Szczudlo, Susan Branford, PhD
Journal: Blood
Blood (2011) 118 (21): 606.
https://doi.org/10.1182/blood.V118.21.606.606
Published: 2011
Journal Articles

Imatinib Mesilate Versus Allogeneic Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia in First Chronic Phase - A Brazilian Point of View.

Henrique Bittencourt, MD, Vaneuza Funke, MD, Laura Fogliatto, MD, Simone Magalhaes, MD, Daniela Setubal, MD, Alessandra Paz, MD, Antonio V. Macedo, MD, Jefferson Ruiz, MD, Ana Paula Azambuja, MD, Lucia M.R. Silla, MD, Nelma Clementino, MD, Ricardo Pasquini, MD
Journal: Blood
Blood (2007) 110 (11): 1096.
https://doi.org/10.1182/blood.V110.11.1096.1096
Published: 2007
Journal Articles

Cardiotoxicity of Imatinib Mesylate - A Prospective Cross-Sectional Study.

Henrique Bittencourt, MD, Milena S. Marcolino, MD, Nelma Clementino, MD, Vitor F. Xavier, MD, Marcia M. Barbosa, MD, Maria do Carmo P. Nunes, MD, Antonio L. Ribeiro
Journal: Blood
Blood (2007) 110 (11): 4571.
https://doi.org/10.1182/blood.V110.11.4571.4571
Published: 2007
Journal Articles

Gleevec as Therapy for CML Relapsed after Allogeneic Stem Cell Transplantation: High Rate of BCR-ABL PCR Negativity and Donor Graft Reconstitution.

Vaneuza A.M. Funke, MD, MS, Samir K. Nabhan, MD, Michel M. Oliveira, MD, Jefferson Ruiz, MD, Daniela C. Setubal, MD, Ana Paula Azambuja, MD, Denise H. Lima, ARNP, Terezinha K. Kojo, ARNP, Henrique Bitencourt, MD, Nelson Hamerschlak, MD, Nelma Clementino, MD, Heliz Regina A. Neves, MS, Ricardo Pasquini, MD PHD
Journal: Blood
Blood (2006) 108 (11): 3671.
https://doi.org/10.1182/blood.V108.11.3671.3671
Published: 2006